1. Scrip
  2. >>New Products

Gilead HIV Sales Getting Boost From Switches To TAF-Based Combos

 
• By Joseph Haas

Eighty percent of patients who’ve received Genvoya so far are switched over from older Gilead regimens, while 10% have switched from non-Gilead drugs. In terms of cumulative prescriptions, the Genvoya launch is outpacing the launch of predecessor drug Stribild to date.

The future of Gilead Sciences Inc.’s HIV business depends on switching patients over to its newer HIV single-tablet regimens where the older Viread is replaced with the prodrug tenofovir alafenamide (TAF), and not only did it report strong starts in the third quarter, it has new evidence in hand that should help it convert patients from the old to the new.

In an interview with Scrip, Gilead’s VP-HIV Medical Affairs David Piontkowsky noted that at the recent 2016 Glasgow HIV meeting treatment guidelines have been updated to either prefer TAF to Viread (tenofovir disoproxil (TDF) or place it on par, and that

Gilead reported Nov. 1 that its HIV and other non-HCV antiviral products portfolio posted sales of $3.5bn during the third quarter, up 32% from $2.9bn in third quarter 2015

More from New Products

Strong Showing For Bayer’s Pharma Business In Uncertain Times

 
• By Kevin Grogan

As CEO Anderson backs high prices for innovative drugs in Europe

Biopharma Deals ROI Has Fallen And Market Instability Could Make It Worse

 
• By Andrew McConaghie

Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Verastem Wins Approval For Novel Drug Combo In Rare Ovarian Cancer

 
• By Jessica Merrill

The novel RAF/MEK inhibitor and FAK inhibitor are the first treatment approved specifically for KRAS-mutated recurrent low-grade serious ovarian cancer (LGSOC).

More from Scrip

Merck’s Welireg Adrenal Tumor Rollout Targets Specialized Centers

 
• By Alaric DeArment

The drugmaker won US FDA approval for the HIF-2α inhibitor in pheochromocytoma and paraganglioma, a rare cancer of the adrenal glands, in adolescents and adults.

Most Favored Nation Policy ‘Lazy, Misguided,’ But US Price Reforms Politically ‘Inevitable’

 
• By Cathy Kelly

Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.

Merck KGaA Braces For Volatility But Does Not Expect Europe To Budge On Pricing

 
• By Andrew McConaghie

Shares are hit as German conglomerate lowers revenue forecast.